



VISION and MISSION

UNMCCC's vision is to continuously drive discovery and innovation for better cancer prevention, diagnostics, treatments and patient-centered care.

Discovering the Cures, Elevating Every Life.










The mission of the UNMCCC is to reduce the cancer burden and overcome the differences in cancer risk, incidence, and outcomes in the people of New Mexico and beyond through:

- Ground-breaking transdisciplinary research
- Translation of discoveries to clinical and community interventions
- Impactful and respectful bi-directional community engagement
- Education, and training of the cancer workforce and leadership of tomorrow
- The delivery of exceptional patient-centered cancer care



UNMCCC Cancer Center History





UNM Comprehensive Cancer Center One of 57 NCI-designated Comprehensive Cancer Centers




74 NCI Cancer Centers

- Top 3% of Cancer Centers in the Nation
- 36 States
- Core of NCI Extramural Research Mission: >80% Extramural Budget
- Discovery science engine and translation to clinical trials and interventions.
- Deeply engage communities and build community networks
- Train the nation's cancer workforce



UNM Comprehensive Cancer Center Differentiators



- UNMCCC serves a unique catchment area with multiethnic populations through respectful, bidirectional engagement and communication.
- The New Mexico Cancer Research Alliance provides a partnership with community-based health systems and oncology providers. The NMCRA, a 501(c)(3) collaborative network established by UNMCCC in 2003, is funded as an NCI Community Oncology Research Program (NCORP; 2UG1CA189856-06; PI Muller).
- Partner Lovelace Biomedical Research Institute with complementary lung cancer prevention, screening and treatment, as well as tobacco and e-cigarette research.
- Project ECHO a tele-mentoring platform developed at UNM and used world-wide is used by UNMCCC to improve cancer patient outcomes through education, training and care management.



What Makes the UNM Comprehensive Cancer Center Unique

- The Official Cancer Center of the state of New Mexico
- The only cancer center in New Mexico to hold the NCI Comprehensive Cancer Center designation, delivering cancer treatment not available elsewhere within a 500-mile radius.
- Conducts cutting-edge cancer research and translates discoveries to interventions
- Our patients receive state-of-the-art care all in one place: expert multi-disciplinary treatment planning; access to novel clinical trials; and personalized treatment.

UNM Cancer Center by the Numbers (2024)

16,501

Patients Seen 104,414

Ambulatory Clinic Visits 18,185

Therapeutic Infusions

12,727

Radiation Treatment 136

Board Certified Oncologists

123

Research Faculty

55%

Patients from Bernalillo County

45%

Patients from outside of Bernalillo County

138

Clinical Trials 1,563

Clinical Trials
Participants

\$18.3 Million

Uncompensated Care



UNMCCC: Multidisciplinary Patient Care

Clinical Working Group (CWG) by disease site

- Breast
- Head & Neck
- GI
- GYN ONC
- GU

- Lung
- Heme and BMT
- Melanoma/Sarcoma
- Pediatric Oncology
- Community Oncology



- APPs
- Nurses
- Nurse navigators
- MAs

Clinical Services

- · Research nurse & coordinators
- Data coordinators
- Regulatory and compliance

Clinical Research

- Scheduling
- Social work
- Nutrition
- Prior authorization

Support Services



Building for the Future

Expansion of Clinical Research and Treatment Space at the UNMCCC, 50,000 sq ft.

Space for state-of-the art radiation oncology technologies and procedures,

including the only MRI-Linac in NM
Expansion of Theranostics
Growth of the only Bone Marrow/Stem
Cell Transplantation accredited
program in NM

20 bed wing at UNMH for Medical
 Oncology and cell-based therapies

Expansion of clinical research and workforce training programs

Groundbreaking December 14, 2023





Building for the Future



- Expanded radiation oncology services with advanced image-guided radiation therapy and Stereotactic RadioSurgery (SRS) capabilities:
- State-of-the-art Magnetic Resonance Linear Accelerator (MR LINAC).
- Features the latest image-guided radiotherapy for real-time imaging of patient tumors while simultaneously undergoing active treatment.
- Technology supports future advancements with Artificial Intelligence (AI) and incorporation of machine learning algorithms to provide adaptive treatments that minimizes side effects while maximizing clinical efficacy.
- Only one of its type in New Mexico. New platform for training and clinical research.



Building for the Future


- The newly-installed Versa HD can be used to perform intensity modulated radiation therapy, stereotactic body radiation therapy and stereotactic radiosurgery for a wide variety of tumor types, a noninvasive procedure that delivers high dose radiation to a tumor but a much lower dose to surrounding tissues, thus killing tumor cells but sparing the nearby cells.
- The plan is to have three Versa
 HD machines by the end of 2026.






Building for the Future UNM BMT Program











USC Norris Comprehensive Cancer Center Keck Medicine of USC





Prajakta Adsul, MBBS, PhD, MPH

Assistant Professor, Internal Medicine

Epidemiology, Biostatistics, and Preventive Medicine



Eric Bartee, PhD

As sociate Professor Internal Medicine Molecular Medicine

*Co-Director Faculty Development (CRTECC)



Eliseo F. Castillo, PhD

As sociate Professor, Gastroenterology & Hepatology

*Associate Director DEI



Jennifer Gillette, PhD

Professor Pathology

*Associate Director CRTECC



Neda Hashemi, MD

As sociate Professor, SOM - Internal Medicine Hematology/Oncology

PRMC chair

NCI Early Career Cancer Clinical Investigator



David Lee, MD, PhD

Associate Professor Internal Medicine, Hematology/Oncolog y, Director of Radiation Oncology



Shuguang Leng, MD, PhD

As sistant Professor, Internal Medicine, Epidemiology, Biostatistics, and Preventive Medicine



Diane Lidke, PhD

Professor, Pathology

Fluorescence Microscopy Shared Resource Director



Jacklyn Nemunaitis, MD

Assistant Professor, Department of Internal Medicine, Division of Hematology/Oncology



Viswanathan Palanisamy, PhD

Professor, Internal Medicine Molecular Medicine *Director ATGSR



Jessica Valdez, MD, MPH


Assistant Professor, Department of Pediatrics, Division of Pediatric Oncology



Second Cohort in 2025



*Co-Director CCPS



Española NM, April 2024



Thank You





Questions



